Athena Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.47M Hold
52,302
0.76% 31
2025
Q4
$1.3M Hold
52,302
0.67% 34
2025
Q3
$1.33M Sell
52,302
-32
-0.1% -$790 0.69% 31
2025
Q2
$1.27M Hold
52,334
0.71% 33
2025
Q1
$1.33M Buy
52,334
+966
+2% +$25.3K 0.8% 27
2024
Q4
$1.36M Sell
51,368
-809
-2% -$21.9K 0.79% 23
2024
Q3
$1.51M Buy
52,177
+165
+0.3% +$4.81K 0.86% 20
2024
Q2
$1.46M Buy
52,012
+713
+1% +$19.6K 0.88% 20
2024
Q1
$1.42M Buy
51,299
+840
+2% +$23.3K 0.85% 21
2023
Q4
$1.45M Buy
50,459
+355
+0.7% +$10.7K 0.94% 18
2023
Q3
$1.66M Buy
50,104
+210
+0.4% +$7.43K 1.19% 15
2023
Q2
$1.83M Buy
49,894
+508
+1% +$19.8K 1.26% 11
2023
Q1
$2.01M Buy
49,386
+219
+0.4% +$9.46K 1.45% 10
2022
Q4
$2.52M Hold
49,167
1.85% 9
2022
Q3
$2.15M Hold
49,167
1.81% 9
2022
Q2
$2.58M Buy
49,167
+4,026
+9% +$205K 2.03% 9
2022
Q1
$2.34M Buy
+45,141
New +$2.34M 1.82% 10

Other funds holding PFE

Athena Investment Management's PFE Position: Q1 2026 in Review

Athena Investment Management held its Pfizer (PFE) position steady in Q1 2026 at 52,302 shares worth $1.47M. The position accounts for 0.76% of the portfolio, ranked #31.

Athena Investment Management first reported a position in PFE in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.58M in Q2 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Athena Investment Management held 52,302 shares of Pfizer worth $1.47M as of Q1 2026.
  • Athena Investment Management left its Pfizer share count unchanged in Q1 2026.
  • Pfizer made up 0.76% of Athena Investment Management's portfolio in Q1 2026, its #31 holding.
  • Athena Investment Management first reported a position in Pfizer in Q1 2022 and has held it in 17 quarters since.
  • Athena Investment Management's Pfizer position peaked at $2.58M in Q2 2022.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Athena Investment Management's 13F filing for Q1 2026, filed 12 May 2026.